METASTATIC BREAST CANCER
Clinical trials for METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted attack on advanced breast cancer halted
Disease control TerminatedThis study tested a targeted drug called futibatinib, alone or with hormone therapy, for people with advanced breast cancer that had spread and had specific genetic changes (FGFR amplifications). The goal was to see if the drug could shrink tumors and control the cancer's growth.…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug tested for Tough-to-Treat breast cancer that returns quickly
Disease control TerminatedThis study aimed to test a drug called Trastuzumab Deruxtecan (T-DXd) for people with advanced HER2-positive breast cancer whose cancer returned within a year of finishing prior treatment. The goal was to see if the drug could shrink tumors and control the disease. The study was …
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Personalized test aims to match late-stage breast cancer patients with effective chemotherapy
Disease control TerminatedThis study tested whether a chemotherapy drug called ixabepilone could help control advanced breast cancer that had stopped responding to standard treatments. Researchers used a special test (the Ixabepilone DRP) to try to predict which patients' tumors were most likely to respon…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Trial for tough breast cancer cases halted early
Disease control TerminatedThis study tested an experimental drug called BDC-1001, both alone and combined with an existing drug (pertuzumab), for people with advanced HER2-positive breast cancer that had worsened after standard treatments. The goal was to see if the treatment could shrink tumors and was s…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC